284 related articles for article (PubMed ID: 30895827)
1. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
2. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
3. Use of methotrexate in patients with inflammatory bowel diseases.
Preiss JC; Zeitz M
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S151-5. PubMed ID: 21044450
[TBL] [Abstract][Full Text] [Related]
4. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory Bowel Disease - Non-biological treatment.
Magro F; Cordeiro G; Dias AM; Estevinho MM
Pharmacol Res; 2020 Oct; 160():105075. PubMed ID: 32653651
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
Renna S; Cottone M; Orlando A
World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
[TBL] [Abstract][Full Text] [Related]
7. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies.
Winter RW; Burakoff R
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):95-97. PubMed ID: 27900879
[No Abstract] [Full Text] [Related]
8. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
9. Personalizing therapy for inflammatory bowel diseases.
Ananthakrishnan AN
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):549-58. PubMed ID: 23985004
[TBL] [Abstract][Full Text] [Related]
10. How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases.
Schreiber S; Vermeire S
Gastroenterology; 2016 May; 150(5):1061-1066. PubMed ID: 27018485
[No Abstract] [Full Text] [Related]
11. Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
Korelitz BI
World J Gastroenterol; 2013 May; 19(20):2979-84. PubMed ID: 23716977
[TBL] [Abstract][Full Text] [Related]
12. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease: long-term therapeutic challenges.
Ashton JJ; Green Z; Kolimarala V; Beattie RM
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1049-1063. PubMed ID: 31657969
[No Abstract] [Full Text] [Related]
14. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
15. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry RB; Irving PM
J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
[No Abstract] [Full Text] [Related]
16. An evidence-based systematic review on medical therapies for inflammatory bowel disease.
Talley NJ; Abreu MT; Achkar JP; Bernstein CN; Dubinsky MC; Hanauer SB; Kane SV; Sandborn WJ; Ullman TA; Moayyedi P;
Am J Gastroenterol; 2011 Apr; 106 Suppl 1():S2-25; quiz S26. PubMed ID: 21472012
[No Abstract] [Full Text] [Related]
17. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States.
Hadi YB; Thakkar S; Shah-Khan SM; Hutson W; Sarwari A; Singh S
Gastroenterology; 2021 Oct; 161(4):1336-1339.e3. PubMed ID: 34144044
[No Abstract] [Full Text] [Related]
19. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
20. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
Sorrentino D; Fogel S; Van den Bogaerde J
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
